Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study

References

• Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, et al. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS 2010;24:1228–30.
   PubMed Web of Science ®Google Scholar
• Morlat P, Roussillon C, Henard S, Salmon D, Bonnet F, Cacoub P, et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since2000. AIDS 2014;28:1181–91.
   Google Scholar
• Rodger AJ, Lodwick R, Schechter M, Deeks S, Amin J, Gilson R, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS 2013;27:973–9.
   PubMed Web of Science ®Google Scholar
• Reinsch N, Neuhaus K, Esser S, Potthoff A, Hower M, Mostardt S, et al. Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART study . Eur J Prev Cardiol 2012;19:267–74.
   PubMed Web of Science ®Google Scholar
• Duval X, Baron G, Garelik D, Villes V, Dupré T, Leport C, et al. Living with HIV, antiretroviral treatment experience and tobacco smoking: results from a multisite cross-sectional study. Antivir Ther 2008;13:389–97.
   PubMed Web of Science ®Google Scholar
• Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, Law M, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010;24:1537–48.
   PubMed Web of Science ®Google Scholar
• Bavinger C, Bendavid E, Niehaus K, Olshen RA, Olkin I, Sundaram V, et al. Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review. PLoS One 2013;8:e59551.
   PubMed Web of Science ®Google Scholar
• El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4 + count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283–96.
   PubMed Web of Science ®Google Scholar
• Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010;170:1228–38.
   PubMed Web of Science ®Google Scholar
• Worm W, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. J Infect Dis 2010;201:318–30.
   PubMed Web of Science ®Google Scholar
• Achhra AC, Boyd MA. Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature. AIDS Res Ther 2013;10:33.
   PubMed Web of Science ®Google Scholar
• Monforte Ad, Reiss P, Ryom L, El-Sadr W, Dabis F, De Wit S, et al. Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events. AIDS 2013;27:407–15.
   PubMed Web of Science ®Google Scholar
• Aberg JA, Tebas P, Overton ET, Gupta SK, Sax PE, Landay A, et al. Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses 2012;28:1184–95.
   PubMed Web of Science ®Google Scholar
• Minami R, Yamamoto M, Takahama S, Ando H, Miyamura T, Suematsu E. Comparison of the influence of four classes of HIV antiretrovirals on adipogenic differentiation: the minimal effect of raltegravir and atazanavir. J Infect Chemother 2011;17:183–8.
   PubMed Web of Science ®Google Scholar
• Lam YM, McBride KL, Amin J, Cordery DV, Kelleher AD, Cooper DA, et al. Switching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNA. PLoS One 2012;7:e31990.
   Web of Science ®Google Scholar
• Delaugerre C, Charreau I, Braun J, Néré ML, de Castro N, Yeni P, et al. Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen. AIDS 2010;24:2391–5.
   PubMed Web of Science ®Google Scholar
• Lake J, McComsey G, Hulgan T, Wanke C, Mangili A, Walmsley S, et al. Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial. HIV Med 2014;15:431–41.
   PubMed Web of Science ®Google Scholar
• Martínez E, D’Albuquerque PM, Llibre JM, Gutierrez F, Podzamczer D, Antela A, et al. Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS 2012;26:2315–26.
   PubMed Web of Science ®Google Scholar
• Silva EF, Charreau I, Gourmel B, Mourah S, Kalidi I, Guillon B, et al. Decreases in inflammatory and coagulation biomarkers levels in HIV-infected patients switching from enfuvirtide to raltegravir: ANRS 138 substudy. J Infect Dis 2013;208:892–7.
   PubMed Web of Science ®Google Scholar
• Gupta SK, Mi D, Moe SM, Dubé MP, Liu Z. Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial. J Acquir Immune Defic Syndr 2013;64:279–83.
   PubMed Web of Science ®Google Scholar
• Flammer AJ, Vo NT, Ledergerber B, Hermann F, Gämperli A, Huttner A, et al. Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: randomised controlled trial. Heart 2009;95:385–90.
   PubMed Web of Science ®Google Scholar
• Zhu L, Butterton J, Persson A, Stonier M, Comisar W, Panebianco D, et al. Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals. Antivir Ther 2010;15:1107–14.
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Wenning LA, Mistry GC, Petry AS, Liou SY, Ghosh K, et al. Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clin Infect Dis 2008;47: 137–40.
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Ripamonti D, Baldelli S, Cozzi V, Conti F, Clementi E. Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients. Ther Drug Monit 2010;32:782–6.
   PubMed Web of Science ®Google Scholar
• Neely M, Decosterd L, Fayet A, Lee JS, Margol A, Kanani M, et al. Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers. Antimicrob Agents Chemother 2010;54:4619–25.
   PubMed Web of Science ®Google Scholar
• Jansen A, Colbers EP, van der Ven AJ, Richter C, Rockstroh JK, Wasmuth JC, et al. Pharmacokinetics of the combination raltegravir/atazanavir in HIV-1-infected patients. HIV Med 2013;14:449–52.
   PubMed Web of Science ®Google Scholar
• Carey D, Pett SL, Bloch M, Wand H, MacRae K, Beileiter K, et al. A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults. J Acquir Immune Defic Syndr 2012;60:143–9.
   PubMed Web of Science ®Google Scholar
• Cordery DV, Hesse K, Amin J, Cooper DA. Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients. Antivir Ther 2010;15:1035–8.
   PubMed Web of Science ®Google Scholar
• Gupta S, Lataillade M, Farber S, Kozal MJ. Raltegravir with unboosted atazanavir 300 mg twice daily in antiretroviral treatment-experienced participants. J Int Assoc Physicians AIDS Care (Chic) 2009;8:87–92.
   PubMedGoogle Scholar
• Kozal MJ, Lupo S, DeJesus E, Molina JM, McDonald C, Raffi F, et al. A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results. HIV Clin Trials 2012;13:119–30.
   PubMed Web of Science ®Google Scholar
• Vandenhende MA, Bellecave P, Recordon-Pinson P, Reigadas S, Bidet Y, Bruyand M, et al. Prevalence and evolution of low frequency HIV drug resistance mutations detected by ultra deep sequencing in patients experiencing first line antiretroviral therapy failure. PLoS One 2014; 9:e86771.
   Web of Science ®Google Scholar
• Mukherjee R, Jensen ST, Male F, Bittinger K, Hodinka RL, Miller MD, et al. Switching between raltegravir resistance pathways analyzed by deep sequencing. AIDS 2011; 25:1951–9.
   PubMed Web of Science ®Google Scholar
• Armenia D, Vandenbroucke I, Fabeni L, Van Marck H, Cento V, D’Arrigo R, et al. Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing. J Infect Dis 2012;205:557–67.
   PubMed Web of Science ®Google Scholar
• Noguera-Julian M, Casadellà M, Pou C, Rodríguez C, Pérez-Álvarez S, Puig J, et al. Stable HIV-1 integrase diversity during initial HIV-1 RNA decay suggests complete blockade of plasma HIV-1 replication by effective raltegravir- containing salvage therapy. Virol J 2013;10:350.
   PubMed Web of Science ®Google Scholar
• Morlat P. Rapport 2013 sur la prise en charge médicale des personnes vivant avec le VIH. Available at: http://www.sante.gouv.fr [accessed April 15, 2014].
   Google Scholar
• Eron JJ, Cooper DA, Steigbigel RT, Clotet B, Gatell JM, Kumar PN, et al. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infect Dis 2013;13:587–96.
   PubMed Web of Science ®Google Scholar
• Di Giambenedetto S, Torti C, Prosperi M, Manca N, Lapadula G, Paraninfo G, et al. Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study. Infection 2009;37:438–44.
   PubMed Web of Science ®Google Scholar